Literature DB >> 2305682

Medical costs of coronary artery disease in the United States.

E H Wittels1, J W Hay, A M Gotto.   

Abstract

A model has been developed to determine the cost of coronary artery disease (CAD) based on the 5 primary events identified in the Framingham Study: acute myocardial infarction, angina pectoris, unstable angina pectoris, sudden death and nonsudden death. The costs for diagnostic and therapeutic service for patients with CAD were linked to medical decision algorithms outlining the diagnosis and management of patients with CAD. Because CAD is a changing illness not represented by a single event, the algorithm tracked patients for 5 years after the time of diagnosis, or until death, to develop average cost estimates. The estimated 5-year costs (in 1986 United States dollars) of the 5 CAD events were: acute myocardial infarction $51,211, angina pectoris $24,980, unstable angina pectoris $40,581, sudden death $9,078 and nonsudden death $19,697. The costs of major CAD surgical procedures were also calculated because of their impact on health care costs for patients with CAD. These include: coronary artery bypass surgery per case over 5 years $32,465, and angioplasty per case over 5 years $26,916. The high cost of CAD reflects the improved technology and more effective and expensive therapies now available.

Entities:  

Mesh:

Year:  1990        PMID: 2305682     DOI: 10.1016/0002-9149(90)90806-c

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

Review 1.  Pharmacoeconomics of genetically engineered drugs.

Authors:  A J Jones-Grizzle; J L Bootman
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

2.  Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents.

Authors:  P Gazzaniga; L Garattini
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

Review 3.  Costs of illness in cost-effectiveness analysis. A review of the methodology.

Authors:  T A Hodgson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

4.  Potential health benefits of nutrition label changes.

Authors:  G A Zarkin; N Dean; J A Mauskopf; R Williams
Journal:  Am J Public Health       Date:  1993-05       Impact factor: 9.308

Review 5.  A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.

Authors:  Ching-Yun Wei; Ruben G W Quek; Guillermo Villa; Shravanthi R Gandra; Carol A Forbes; Steve Ryder; Nigel Armstrong; Sohan Deshpande; Steven Duffy; Jos Kleijnen; Peter Lindgren
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

6.  Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

Authors:  Joel W Hay; Kimberly L Sterling
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  The invasive management of angina: issues for consumers and commissioners.

Authors:  D Gunnell; I Harvey; L Smith
Journal:  J Epidemiol Community Health       Date:  1995-08       Impact factor: 3.710

Review 8.  Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.

Authors:  J W Hay; W M Yu; T Ashraf
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.558

9.  Effects of Increasing Aridity on Ambient Dust and Public Health in the U.S. Southwest Under Climate Change.

Authors:  Pattanun Achakulwisut; Susan C Anenberg; James E Neumann; Stefani L Penn; Natalie Weiss; Allison Crimmins; Neal Fann; Jeremy Martinich; Henry Roman; Loretta J Mickley
Journal:  Geohealth       Date:  2019

10.  Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease.

Authors:  Sandra Spronk; Johanna L Bosch; Constance Ryjewski; Judith Rosenblum; Guido C Kaandorp; John V White; M G Myriam Hunink
Journal:  PLoS One       Date:  2008-12-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.